For decades, WeightWatchers told the world that weight loss came through sheer willpower-“choice, not chance,” as its founder, Jean Nidetch, said in the 1960s. Now, thanks to new drugs like Ozempic, Sistani is rejecting that blame-the-dieter approach in favor of the view that obesity is an illness-one her company can help cure, The Wall Street Journal’s Erich Schwartzel reports. So that it could prescribe weight-loss drugs, the company paid $106M to acquire a telehealth company called Sequence, and has opted to apologize for much of what made it iconic.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on WW:
- WeightWatchers Enhances Enterprise Offering with Full-Spectrum Access to Weight Health
- WeightWatchers enhances WeightWatchers for Business offering
- Unusually active option classes on open October 5th
- WW upgraded, Macy’s downgraded: Wall Street’s top analyst calls
- Craig-Hallum upgrades WW to Hold amid enthusiasm for GLP-1 medications